US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
DK0669836T3
(da)
*
|
1992-11-13 |
1996-10-14 |
Idec Pharma Corp |
Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
|
US7744877B2
(en)
*
|
1992-11-13 |
2010-06-29 |
Biogen Idec Inc. |
Expression and use of anti-CD20 Antibodies
|
US5736137A
(en)
*
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
US5595721A
(en)
*
|
1993-09-16 |
1997-01-21 |
Coulter Pharmaceutical, Inc. |
Radioimmunotherapy of lymphoma using anti-CD20
|
US5885574A
(en)
*
|
1994-07-26 |
1999-03-23 |
Amgen Inc. |
Antibodies which activate an erythropoietin receptor
|
US8771694B2
(en)
*
|
1994-08-12 |
2014-07-08 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
|
WO1996004925A1
(en)
*
|
1994-08-12 |
1996-02-22 |
Immunomedics, Inc. |
Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
|
US20030180290A1
(en)
*
|
1995-06-07 |
2003-09-25 |
Idec Pharmaceuticals Corporation |
Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
|
US6373497B1
(en)
|
1999-05-14 |
2002-04-16 |
Zight Corporation |
Time sequential lookup table arrangement for a display
|
US7033589B1
(en)
*
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US6893636B2
(en)
*
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
US6991790B1
(en)
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
US6171586B1
(en)
*
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
US20030161823A1
(en)
*
|
1998-08-31 |
2003-08-28 |
Neta Ilan |
Therapeutic and cosmetic uses of heparanases
|
US6699672B1
(en)
|
1997-09-02 |
2004-03-02 |
Insight Biopharmaceuticals Ltd. |
Heparanase specific molecular probes and their use research and medical applications
|
US20040213789A1
(en)
*
|
1997-09-02 |
2004-10-28 |
Oron Yacoby-Zeevi |
Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
|
US20020088019A1
(en)
*
|
1997-09-02 |
2002-07-04 |
Oron Yacoby-Zeevi |
Methods of and pharmaceutical compositions for improving implantation of embryos
|
US6177545B1
(en)
*
|
1997-09-02 |
2001-01-23 |
Insight Strategy & Marketing Ltd. |
Heparanase specific molecular probes and their use in research and medical applications
|
US20010006630A1
(en)
*
|
1997-09-02 |
2001-07-05 |
Oron Yacoby-Zeevi |
Introducing a biological material into a patient
|
US6562950B2
(en)
*
|
1997-09-02 |
2003-05-13 |
Insight Strategy & Marketing Ltd. |
Heparanase activity neutralizing anti-heparanase monoclonal antibody
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
DK2180007T4
(da)
*
|
1998-04-20 |
2017-11-27 |
Roche Glycart Ag |
Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
|
NZ528199A
(en)
*
|
1998-08-11 |
2005-06-24 |
Idec Pharma Corp |
Combination therapies for B-cell lyphomas comprising administration of anti-CD20 antibody
|
US20030217375A1
(en)
*
|
1998-08-31 |
2003-11-20 |
Eyal Zcharia |
Transgenic animals expressing heparanase and uses thereof
|
US20010033839A1
(en)
*
|
1999-10-04 |
2001-10-25 |
Emilio Barbera-Guillem |
Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
|
US6224866B1
(en)
|
1998-10-07 |
2001-05-01 |
Biocrystal Ltd. |
Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
|
WO2000027433A1
(en)
*
|
1998-11-09 |
2000-05-18 |
Idec Pharmaceuticals Corporation |
Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants
|
PT1616572E
(pt)
|
1998-11-09 |
2010-11-11 |
Biogen Idec Inc |
Anticorpo quimérico anti-cd20, rituxan, para utilização no tratamento de leucemia linfocítica crónica
|
WO2000029431A1
(en)
*
|
1998-11-17 |
2000-05-25 |
Tanox, Inc. |
Bispecific molecules cross-linking itim and itam for therapy
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
KR101077001B1
(ko)
*
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US20020102208A1
(en)
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
WO2000052178A1
(en)
*
|
1999-03-01 |
2000-09-08 |
Insight Strategy & Marketing Ltd. |
Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
|
MY133346A
(en)
*
|
1999-03-01 |
2007-11-30 |
Biogen Inc |
Kit for radiolabeling ligands with yttrium-90
|
HUP0201009A2
(en)
*
|
1999-05-07 |
2002-07-29 |
Genentech Inc |
Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
|
EP1645291A1
(en)
|
1999-05-07 |
2006-04-12 |
Genentech, Inc. |
Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
|
US7074403B1
(en)
*
|
1999-06-09 |
2006-07-11 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target B-cells
|
ITMI991299A1
(it)
*
|
1999-06-11 |
2000-12-11 |
Consiglio Nazionale Ricerche |
Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
|
US6949245B1
(en)
*
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
JP4579471B2
(ja)
*
|
1999-06-25 |
2010-11-10 |
ジェネンテック, インコーポレイテッド |
抗ErbB2抗体を用いる前立腺癌の処置
|
US20030086924A1
(en)
*
|
1999-06-25 |
2003-05-08 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US20040013667A1
(en)
*
|
1999-06-25 |
2004-01-22 |
Genentech, Inc. |
Treatment with anti-ErbB2 antibodies
|
US7041292B1
(en)
|
1999-06-25 |
2006-05-09 |
Genentech, Inc. |
Treating prostate cancer with anti-ErbB2 antibodies
|
CN1373672A
(zh)
*
|
1999-07-12 |
2002-10-09 |
杰南技术公司 |
应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
|
US6451284B1
(en)
*
|
1999-08-11 |
2002-09-17 |
Idec Pharmaceuticals Corporation |
Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
|
US8557244B1
(en)
|
1999-08-11 |
2013-10-15 |
Biogen Idec Inc. |
Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
|
WO2001013945A1
(en)
*
|
1999-08-23 |
2001-03-01 |
Biocrystal Ltd. |
Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis
|
RU2305561C2
(ru)
*
|
1999-11-08 |
2007-09-10 |
Байоджен Айдек Инк. |
Лечение в-клеточных злокачественных опухолей с использованием антител против cd40l в комбинации с антителами против cd20 и/или химиотерапией и лучевой терапией
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
ATE329610T1
(de)
*
|
2000-02-16 |
2006-07-15 |
Genentech Inc |
Anti-april antikörper und hybridomazellen
|
US20030185796A1
(en)
*
|
2000-03-24 |
2003-10-02 |
Chiron Corporation |
Methods of therapy for non-hodgkin's lymphoma
|
CN1981868A
(zh)
*
|
2000-03-31 |
2007-06-20 |
拜奥根Idec公司 |
抗细胞因子抗体或拮抗剂与抗-cd20在b细胞淋巴瘤治疗中的联合应用
|
EP1272647B1
(en)
*
|
2000-04-11 |
2014-11-12 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
CA2399940A1
(en)
|
2000-04-13 |
2001-10-25 |
The Rockefeller University |
Enhancement of antibody-mediated immune responses
|
JP2003531178A
(ja)
*
|
2000-04-25 |
2003-10-21 |
アイデック ファーマスーティカルズ コーポレイション |
中枢神経系リンパ腫治療用のリツキシマブのクモ膜下投与
|
AU2001259271A1
(en)
*
|
2000-04-28 |
2001-11-12 |
Millennium Pharmaceuticals, Inc. |
14094, a novel human trypsin family member and uses thereof
|
JP2003534292A
(ja)
*
|
2000-05-19 |
2003-11-18 |
ジェネンテック・インコーポレーテッド |
Erbbアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ
|
EP2052742A1
(en)
*
|
2000-06-20 |
2009-04-29 |
Biogen Idec Inc. |
Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
|
CA2412901A1
(en)
*
|
2000-06-22 |
2001-12-27 |
Idec Pharmaceutical Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
US20060029604A1
(en)
*
|
2000-06-28 |
2006-02-09 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
|
US20060034828A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
|
US20060034830A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
|
US20060024304A1
(en)
*
|
2000-06-28 |
2006-02-02 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
|
AU6461201A
(en)
*
|
2000-07-12 |
2002-01-21 |
Idec Pharma Corp |
Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
|
KR20040023565A
(ko)
*
|
2000-09-18 |
2004-03-18 |
아이덱 파마슈티칼즈 코포레이션 |
B 세포 고갈/면역조절 항체 조합을 이용한 자가면역질환의 치료를 위한 조합 요법
|
AU2002213357A1
(en)
*
|
2000-10-20 |
2002-05-06 |
Idec Pharmaceuticals Corporation |
Variant igg3 rituxan r and therapeutic use thereof
|
US7906492B2
(en)
*
|
2001-01-16 |
2011-03-15 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
US7507724B2
(en)
*
|
2001-01-16 |
2009-03-24 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
AU2008200400B2
(en)
*
|
2001-01-17 |
2012-06-07 |
Aptevo Research And Development Llc |
Binding domain-immunoglobulin fusion proteins
|
JP2004525620A
(ja)
*
|
2001-01-17 |
2004-08-26 |
トルビオン・ファーマシューティカルズ・インコーポレイテッド |
結合ドメイン−免疫グロブリン融合タンパク質
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
IL157145A0
(en)
|
2001-01-31 |
2004-02-08 |
Idec Pharma Corp |
Use of dc23 antagonists for the treatment of neoplastic disorders
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
WO2002060485A2
(en)
|
2001-01-31 |
2002-08-08 |
Idec Pharmaceuticals Corporation |
Use of immunoregulatory antibodies in the treatment of neoplastic disorders
|
US20020159996A1
(en)
*
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20030003097A1
(en)
*
|
2001-04-02 |
2003-01-02 |
Idec Pharmaceutical Corporation |
Recombinant antibodies coexpressed with GnTIII
|
WO2002078766A2
(en)
*
|
2001-04-02 |
2002-10-10 |
Genentech, Inc. |
Combination therapy
|
EP1383544A4
(en)
*
|
2001-04-09 |
2007-12-12 |
Progenics Pharm Inc |
IMMUNOTOXINS ANTI-CD19
|
US20020193569A1
(en)
*
|
2001-06-04 |
2002-12-19 |
Idec Pharmaceuticals Corporation |
Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
|
JP2004532642A
(ja)
*
|
2001-06-13 |
2004-10-28 |
ジェネンテック・インコーポレーテッド |
動物細胞の培養方法と動物細胞でのポリペプチド産生
|
HUP0500992A3
(en)
*
|
2001-08-03 |
2007-11-28 |
Genentech Inc |
Tacis and br3 polypeptides and uses thereof
|
EP1423510A4
(en)
*
|
2001-08-03 |
2005-06-01 |
Glycart Biotechnology Ag |
ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
|
US7255858B2
(en)
*
|
2001-08-10 |
2007-08-14 |
University Of Virginia Patent Foundation |
Enhancing the efficacy of immunotherapies by supplementing with complement
|
ATE448077T1
(de)
*
|
2001-09-17 |
2009-11-15 |
Life Technologies Corp |
Nanokristalle
|
US7205048B2
(en)
*
|
2001-09-17 |
2007-04-17 |
Invitrogen Corporation |
Functionalized fluorescent nanocrystal compositions and methods of making
|
US7214428B2
(en)
*
|
2001-09-17 |
2007-05-08 |
Invitrogen Corporation |
Highly luminescent functionalized semiconductor nanocrystals for biological and physical applications
|
EP1438583B1
(en)
|
2001-09-20 |
2009-09-16 |
Board of Regents, The University of Texas System |
Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
|
EP2298354B1
(en)
|
2001-10-10 |
2014-03-19 |
ratiopharm GmbH |
Remodelling and glycoconjugation of interferon-beta
|
US8323903B2
(en)
*
|
2001-10-12 |
2012-12-04 |
Life Technologies Corporation |
Antibody complexes and methods for immunolabeling
|
US20050069962A1
(en)
|
2001-10-12 |
2005-03-31 |
Archer Robert M |
Antibody complexes and methods for immunolabeling
|
DK1436427T3
(da)
*
|
2001-10-19 |
2008-12-08 |
Chru Tours |
Fremgangsmåde og sammensætning til at vurdere antistofbehandlingsrespons
|
HUP0600342A3
(en)
*
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
US6671189B2
(en)
*
|
2001-11-09 |
2003-12-30 |
Minebea Co., Ltd. |
Power converter having primary and secondary side switches
|
EA007905B1
(ru)
|
2001-11-16 |
2007-02-27 |
Байоджен Айдек Инк. |
Полицистронная экспрессия антител
|
US20060024292A1
(en)
*
|
2001-12-27 |
2006-02-02 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
|
ATE417858T1
(de)
|
2002-02-05 |
2009-01-15 |
Genentech Inc |
Proteinaufreinigung
|
JP2005517025A
(ja)
|
2002-02-08 |
2005-06-09 |
エクサイト セラピーズ, インコーポレイテッド |
免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法
|
US8287864B2
(en)
*
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
CA2476166C
(en)
*
|
2002-02-14 |
2011-11-15 |
Immunomedics, Inc. |
Anti-cd20 antibodies and fusion proteins thereof and methods of use
|
US20040002587A1
(en)
*
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
KR101017732B1
(ko)
*
|
2002-03-01 |
2011-02-28 |
이뮤노메딕스, 인코오포레이티드 |
내재화 항-cd74 항체 및 그 이용방법
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8361464B2
(en)
|
2002-03-01 |
2013-01-29 |
Immunomedics, Inc. |
Anthracycline-Antibody Conjugates for Cancer Therapy
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20090042291A1
(en)
*
|
2002-03-01 |
2009-02-12 |
Xencor, Inc. |
Optimized Fc variants
|
US20030180292A1
(en)
*
|
2002-03-14 |
2003-09-25 |
Idec Pharmaceuticals |
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
|
EP1501369B1
(en)
|
2002-04-26 |
2015-06-24 |
Genentech, Inc. |
Non-affinity purification of proteins
|
JP2005533863A
(ja)
*
|
2002-07-25 |
2005-11-10 |
ジェネンテック・インコーポレーテッド |
Taci抗体とその用途
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8187593B2
(en)
*
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8044180B2
(en)
*
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
*
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8193318B2
(en)
*
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
EP2345671B8
(en)
|
2002-09-27 |
2023-01-11 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
DK3284753T3
(da)
*
|
2002-10-17 |
2021-07-05 |
Genmab As |
Humane monoklonale antistoffer mod cd20 til anvendelse i behandlingen af multipel sclerose
|
JP4033390B2
(ja)
*
|
2002-10-30 |
2008-01-16 |
独立行政法人科学技術振興機構 |
不死化ナチュラルキラー細胞株
|
JP2006516117A
(ja)
*
|
2002-11-21 |
2006-06-22 |
ジェネンテック・インコーポレーテッド |
抗ErbB2抗体を用いた非悪性疾病または疾患の治療
|
SE0203731D0
(sv)
*
|
2002-12-13 |
2002-12-13 |
Mitra Medical Technology Ab |
Reagent
|
EP1572744B1
(en)
*
|
2002-12-16 |
2010-06-09 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7355008B2
(en)
*
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
JP4177123B2
(ja)
*
|
2003-01-10 |
2008-11-05 |
富士通株式会社 |
配線図形検証方法、プログラム及び装置
|
US20040202666A1
(en)
*
|
2003-01-24 |
2004-10-14 |
Immunomedics, Inc. |
Anti-cancer anthracycline drug-antibody conjugates
|
PL379264A1
(pl)
*
|
2003-01-27 |
2006-08-07 |
Biogen Idec Ma Inc. |
Kompozycje i sposoby leczenia raka przy zastosowaniu IGSF9 i LIV-1
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
*
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
EP2062916A3
(en)
*
|
2003-04-09 |
2009-08-19 |
Genentech, Inc. |
Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
NZ568403A
(en)
*
|
2003-05-09 |
2009-10-30 |
Univ Duke |
CD20-specific antibodies and methods of employing same
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
PT2272868E
(pt)
|
2003-06-05 |
2015-07-07 |
Genentech Inc |
Terapêutica de combinação para distúrbios de células b
|
WO2004108065A2
(en)
*
|
2003-06-09 |
2004-12-16 |
Insight Biopharmaceuticals Ltd. |
Heparanase activity neutralizing anti- heparanase monoclonal antibody and other anti-heparanase antibodies
|
US7754209B2
(en)
|
2003-07-26 |
2010-07-13 |
Trubion Pharmaceuticals |
Binding constructs and methods for use thereof
|
EP3095793B1
(en)
|
2003-07-28 |
2020-03-25 |
Genentech, Inc. |
Reducing protein a leaching during protein a affinity chromatography
|
ZA200600798B
(en)
*
|
2003-07-29 |
2007-06-27 |
Genentech Inc |
Assay for human anti CD20 antibodies and uses therefor
|
MXPA06002134A
(es)
*
|
2003-08-29 |
2006-05-31 |
Genentech Inc |
Terapia de trastornos oculares.
|
US8883147B2
(en)
|
2004-10-21 |
2014-11-11 |
Xencor, Inc. |
Immunoglobulins insertions, deletions, and substitutions
|
US8101720B2
(en)
*
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US20060134105A1
(en)
*
|
2004-10-21 |
2006-06-22 |
Xencor, Inc. |
IgG immunoglobulin variants with optimized effector function
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
WO2005040220A1
(en)
|
2003-10-16 |
2005-05-06 |
Micromet Ag |
Multispecific deimmunized cd3-binders
|
JP4810431B2
(ja)
|
2003-11-04 |
2011-11-09 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
B細胞に関連する癌に対する治療方法
|
CA2542886A1
(en)
*
|
2003-11-05 |
2005-05-19 |
Neelima M. Bhat |
Enhanced b cell cytotoxicity of cdim binding antibody
|
ME01775B
(me)
|
2003-11-05 |
2011-02-28 |
Glycart Biotechnology Ag |
Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
|
EP1697415A1
(en)
|
2003-11-12 |
2006-09-06 |
Biogen Idec MA Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
CN1914226B
(zh)
*
|
2003-11-25 |
2012-02-01 |
达纳-法伯癌症研究院有限公司 |
SARS-CoV抗体及其使用方法
|
KR20060107555A
(ko)
*
|
2003-12-19 |
2006-10-13 |
제넨테크, 인크. |
이식 거부에서 cd20의 검출
|
BRPI0417105A
(pt)
*
|
2003-12-19 |
2007-02-06 |
Genentech Inc |
métodos de tratamento de doenças autoimunológicas em pacientes
|
FR2867982B1
(fr)
*
|
2004-03-26 |
2007-07-20 |
Jean Marie Andrieu |
Procede pour amplifier l'activite de vaccins therapeutiques
|
CN1997893A
(zh)
*
|
2004-04-16 |
2007-07-11 |
健泰科生物技术公司 |
抗体测定法
|
WO2005115453A2
(en)
*
|
2004-04-16 |
2005-12-08 |
Genentech, Inc. |
Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
|
CA2563432A1
(en)
*
|
2004-04-16 |
2005-12-01 |
Genentech, Inc. |
Method for augmenting b cell depletion
|
US7850962B2
(en)
*
|
2004-04-20 |
2010-12-14 |
Genmab A/S |
Human monoclonal antibodies against CD20
|
BRPI0510224A
(pt)
*
|
2004-05-05 |
2007-10-23 |
Genentech Inc |
métodos de prevenção de doença autoimunológica e artigo industrializado
|
CA2566745A1
(en)
|
2004-05-20 |
2005-12-01 |
Zymogenetics, Inc. |
Methods of treating cancer using il-21 and monoclonal antibody therapy
|
PA8635501A1
(es)
*
|
2004-06-04 |
2006-06-02 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del lupus
|
WO2005117978A2
(en)
*
|
2004-06-04 |
2005-12-15 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
US9109255B2
(en)
*
|
2004-06-18 |
2015-08-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for determining responsiveness to antibody therapy
|
SI2471813T1
(sl)
|
2004-07-15 |
2015-03-31 |
Xencor, Inc. |
Optimirane Fc variante
|
NZ552433A
(en)
*
|
2004-07-22 |
2009-10-30 |
Genentech Inc |
Method of treating sjogrenÆs syndrome
|
WO2006012500A2
(en)
|
2004-07-23 |
2006-02-02 |
Genentech, Inc. |
Crystallization of antibodies or fragments thereof
|
EP2213683B1
(en)
|
2004-08-04 |
2013-06-05 |
Mentrik Biotech, LLC |
Variant Fc regions
|
EP1797224B1
(en)
*
|
2004-08-17 |
2012-10-03 |
Life Technologies Corporation |
Synthesis of highly luminescent colloidal particles
|
CN101052654A
(zh)
*
|
2004-08-19 |
2007-10-10 |
健泰科生物技术公司 |
具有改变的效应子功能的多肽变体
|
US7662926B2
(en)
*
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
WO2006028956A2
(en)
*
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Anti-fc-gamma riib receptor antibody and uses therefor
|
US7655229B2
(en)
*
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
EP1791864A2
(en)
*
|
2004-09-08 |
2007-06-06 |
Genentech, Inc. |
Methods of using death receptor ligands and cd20 antibodies
|
CN101048428A
(zh)
*
|
2004-09-08 |
2007-10-03 |
健泰科生物技术公司 |
利用死亡受体配体和cd20抗体的方法
|
AU2005294666A1
(en)
*
|
2004-10-05 |
2006-04-20 |
Genentech, Inc. |
Method for treating vasculitis
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
ATE556126T1
(de)
*
|
2004-10-29 |
2012-05-15 |
Life Technologies Corp |
Funktionalisierte fluoreszierende nanokristalle und verfahren zu deren herstellung und verwendung
|
AU2005335714B2
(en)
|
2004-11-10 |
2012-07-26 |
Macrogenics, Inc. |
Engineering Fc antibody regions to confer effector function
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
EP1817340B1
(en)
|
2004-11-12 |
2012-05-16 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
US20070135620A1
(en)
*
|
2004-11-12 |
2007-06-14 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
GB2420976B
(en)
*
|
2004-11-19 |
2006-12-20 |
Zvi Finkelstein |
Therapeutic implant
|
KR20070086218A
(ko)
*
|
2004-12-17 |
2007-08-27 |
제넨테크, 인크. |
자가면역 질환에 대한 이전 요법에 실패했던 환자에서의,자가면역 질환의 항-혈관신생 요법
|
EP1674479A1
(en)
*
|
2004-12-22 |
2006-06-28 |
Memorial Sloan-Kettering Cancer Center |
Modulation of Fc Gamma receptors for optimizing immunotherapy
|
CA2592390A1
(en)
|
2004-12-22 |
2006-06-29 |
Genentech, Inc. |
Methods for producing soluble multi-membrane-spanning proteins
|
CN101088014B
(zh)
*
|
2004-12-23 |
2012-10-03 |
弗·哈夫曼-拉罗切有限公司 |
在实验动物中检测治疗性抗体
|
EP2096107A1
(en)
|
2004-12-23 |
2009-09-02 |
GPC Biotech AG |
Derivatives of squaric acid with anti-proliferative activity
|
SG173313A1
(en)
|
2005-01-05 |
2011-08-29 |
Biogen Idec Inc |
Cripto binding molecules
|
US20060188495A1
(en)
*
|
2005-01-13 |
2006-08-24 |
Genentech, Inc. |
Treatment method
|
DOP2006000029A
(es)
*
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
AR053579A1
(es)
*
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
US9284375B2
(en)
*
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
*
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
JP5838021B2
(ja)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディとその使用
|
US11254748B2
(en)
|
2005-04-15 |
2022-02-22 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
ZA200708857B
(en)
*
|
2005-04-22 |
2009-01-28 |
Genentech Inc |
Method for treating dementia or alzheimer's disease with a CD30 antibody
|
WO2006117782A2
(en)
*
|
2005-05-04 |
2006-11-09 |
Quark Pharmaceuticals, Inc. |
Recombinant antibodies against cd55 and cd59 and uses thereof
|
EP1888649A2
(en)
*
|
2005-05-09 |
2008-02-20 |
GlycArt Biotechnology AG |
Antigen binding molecules having modified fc regions and altered binding to fc receptors
|
EP1902320B1
(en)
*
|
2005-05-20 |
2010-03-10 |
Genentech, Inc. |
Pretreatment of a biological sample from an autoimmune disease subject
|
AP2007004252A0
(en)
*
|
2005-05-24 |
2007-12-31 |
Avestha Gengraine Tech Pvt Ltd |
A method for the production of a monoclonal antibody to cd20 for the treatment of B-cell lymphoma
|
RS53058B
(en)
|
2005-07-08 |
2014-04-30 |
Biogen Idec Ma Inc. |
SP35 ANTIBODIES AND THEIR APPLICATIONS
|
HUE026303T2
(hu)
*
|
2005-07-25 |
2016-06-28 |
Emergent Product Dev Seattle |
B-sejt csökkentés CD37-specifikus és CD20-specifikus kapcsoló molekulák alkalmazásával
|
US20080279850A1
(en)
*
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
EP1919505A2
(en)
|
2005-07-25 |
2008-05-14 |
Trubion Pharmaceuticals, Inc. |
Single dose use of cd20-specific binding molecules
|
ES2526811T3
(es)
*
|
2005-08-10 |
2015-01-15 |
Macrogenics, Inc. |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
|
US20090215992A1
(en)
*
|
2005-08-19 |
2009-08-27 |
Chengbin Wu |
Dual variable domain immunoglobulin and uses thereof
|
EP2500355A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CA2618482C
(en)
|
2005-08-19 |
2014-10-07 |
Abbott Laboratories |
Dual variable domain immunoglobin and uses thereof
|
AU2006287173A1
(en)
*
|
2005-09-02 |
2007-03-08 |
Glycofi, Inc |
Immunoglobulins comprising predominantly a GICNAcMan3GIcNAc2 glycoform
|
AU2006299429B2
(en)
|
2005-10-03 |
2012-02-23 |
Xencor, Inc. |
Fc variants with optimized Fc receptor binding properties
|
WO2007056411A2
(en)
*
|
2005-11-08 |
2007-05-18 |
Genentech, Inc. |
Method of producing pan-specific antibodies
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
CA2629306A1
(en)
*
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
WO2007064911A1
(en)
*
|
2005-12-02 |
2007-06-07 |
Biogen Idec Inc. |
Anti-mouse cd20 antibodies and uses thereof
|
US8323644B2
(en)
*
|
2006-01-17 |
2012-12-04 |
Sloan-Kettering Institute For Cancer Research |
Therapy-enhancing glucan
|
WO2007102200A1
(ja)
*
|
2006-03-07 |
2007-09-13 |
Osaka University |
抗cd20モノクローナル抗体
|
WO2007106707A2
(en)
*
|
2006-03-10 |
2007-09-20 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant heavy chains and methods of using same
|
WO2007109376A2
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
WO2007127936A2
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
US20080118978A1
(en)
|
2006-04-28 |
2008-05-22 |
Takashi Sato |
Anti-tumor agent
|
US7727525B2
(en)
*
|
2006-05-11 |
2010-06-01 |
City Of Hope |
Engineered anti-CD20 antibody fragments for in vivo targeting and therapeutics
|
WO2008105886A2
(en)
|
2006-05-26 |
2008-09-04 |
Macrogenics, Inc. |
HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
EP2418223A3
(en)
*
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Single-chain multivalent binding proteins with effector function
|
ES2599319T3
(es)
*
|
2006-06-26 |
2017-02-01 |
Macrogenics, Inc. |
Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
|
EP2032159B1
(en)
*
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
US8372399B2
(en)
*
|
2006-08-31 |
2013-02-12 |
Cardiac Pacemakers, Inc. |
Bispecific antibodies and agents to enhance stem cell homing
|
US20080058922A1
(en)
*
|
2006-08-31 |
2008-03-06 |
Cardiac Pacemakers, Inc. |
Methods and devices employing vap-1 inhibitors
|
US8636995B2
(en)
*
|
2006-08-31 |
2014-01-28 |
Cardiac Pacemakers, Inc. |
Methods and devices to regulate stem cell homing
|
US20080112961A1
(en)
*
|
2006-10-09 |
2008-05-15 |
Macrogenics, Inc. |
Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
|
US9382327B2
(en)
*
|
2006-10-10 |
2016-07-05 |
Vaccinex, Inc. |
Anti-CD20 antibodies and methods of use
|
WO2008140603A2
(en)
*
|
2006-12-08 |
2008-11-20 |
Macrogenics, Inc. |
METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
|
US8362217B2
(en)
*
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
WO2008079302A2
(en)
*
|
2006-12-21 |
2008-07-03 |
Millipore Corporation |
Purification of proteins
|
US8569464B2
(en)
*
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
EP2436696B8
(en)
|
2007-01-05 |
2017-12-13 |
University of Zurich |
Anti-beta-amyloid antibody and uses thereof
|
HUE036793T2
(hu)
|
2007-01-09 |
2018-07-30 |
Biogen Ma Inc |
SP35 antitestek és alkalmazásuk
|
DE102007001370A1
(de)
*
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
ATE526017T1
(de)
|
2007-01-22 |
2011-10-15 |
Genentech Inc |
Abscheidung von polyelektrolyten und reinigung von antikörpern
|
US8450348B2
(en)
*
|
2007-02-21 |
2013-05-28 |
Forma Tm, Llc |
Derivatives of squaric acid with anti-proliferative activity
|
CN101668771B
(zh)
|
2007-03-12 |
2013-08-21 |
艾斯巴技术,爱尔康生物医药研究装置有限责任公司 |
单链抗体的基于序列的工程改造和最优化
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
WO2008122039A2
(en)
*
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
FR2915398B1
(fr)
*
|
2007-04-25 |
2012-12-28 |
Lab Francais Du Fractionnement |
"ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
|
EP1995309A1
(en)
*
|
2007-05-21 |
2008-11-26 |
Vivalis |
Recombinant protein production in avian EBx® cells
|
EP2019101A1
(en)
*
|
2007-07-26 |
2009-01-28 |
GPC Biotech AG |
Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
|
KR101530723B1
(ko)
*
|
2007-06-25 |
2015-06-22 |
에스바테크 - 어 노바티스 컴파니 엘엘씨 |
단일 쇄 항체의 서열에 기초한 공학처리 및 최적화
|
SI2158315T1
(sl)
*
|
2007-06-25 |
2016-05-31 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
|
US20090324596A1
(en)
|
2008-06-30 |
2009-12-31 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
US10745701B2
(en)
|
2007-06-28 |
2020-08-18 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
LT3597659T
(lt)
|
2007-07-09 |
2023-05-10 |
Genentech, Inc. |
Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
|
CA2695199C
(en)
|
2007-07-31 |
2016-07-19 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to human cd20 and method of using thereof
|
CA2697482C
(en)
|
2007-09-05 |
2016-05-31 |
F. Hoffmann-La Roche Ag |
Combination therapy with type i and type ii anti-cd20 antibodies
|
CN101868241A
(zh)
*
|
2007-09-28 |
2010-10-20 |
英特瑞克斯顿股份有限公司 |
表达生物治疗分子的治疗基因开关构建物和生物反应器以及它们的应用
|
US20090098118A1
(en)
*
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
WO2009052293A1
(en)
|
2007-10-16 |
2009-04-23 |
Zymogenetics, Inc. |
Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
|
JP2011500608A
(ja)
*
|
2007-10-22 |
2011-01-06 |
オンコリティクス バイオテク,インコーポレーテッド |
増殖性障害の治療レジメン
|
US20090110688A1
(en)
*
|
2007-10-24 |
2009-04-30 |
Georg Fertig |
Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
|
SI2215117T2
(en)
|
2007-10-30 |
2018-04-30 |
Genentech, Inc. |
Purification of the antibody by cation exchange chromatography
|
WO2009117030A2
(en)
*
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Improved compositions for the prevention and treatment of smallpox
|
CN101945667A
(zh)
*
|
2007-12-21 |
2011-01-12 |
健泰科生物技术公司 |
利妥昔单抗不应性类风湿性关节炎患者的疗法
|
KR101616758B1
(ko)
|
2007-12-26 |
2016-04-29 |
젠코어 인코포레이티드 |
FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
ATE548052T1
(de)
|
2008-01-17 |
2012-03-15 |
Philogen Spa |
Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
|
AU2009205995B2
(en)
|
2008-01-18 |
2014-04-03 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
US8883155B2
(en)
*
|
2008-01-28 |
2014-11-11 |
The Regents Of The University Of California |
Methods for treating hematopoietic malignancies
|
ES2592312T3
(es)
*
|
2008-03-25 |
2016-11-29 |
Roche Glycart Ag |
Utilización de un anticuerpo anti-CD20 de tipo II con citotoxicidad celular dependiente de anticuerpos (ADCC) incrementada en combinación con ciclofosfamida, vincristina y doxorrubicina para el tratamiento de linfomas no de Hodgkin
|
SG189730A1
(en)
|
2008-04-02 |
2013-05-31 |
Macrogenics Inc |
Her2/neu-specific antibodies and methods of using same
|
EP3045475B1
(en)
|
2008-04-02 |
2017-10-04 |
MacroGenics, Inc. |
Bcr-complex-specific antibodies and methods of using same
|
DK2132228T3
(da)
*
|
2008-04-11 |
2011-10-10 |
Emergent Product Dev Seattle |
CD37-immunterapeutisk middel og kombination med bifunktionelt kemoterapeutisk middel deraf
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
EP2112152A1
(en)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones as Plk Inhibitors
|
WO2009134738A1
(en)
*
|
2008-04-29 |
2009-11-05 |
Genentech, Inc. |
Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
EP2282769A4
(en)
|
2008-04-29 |
2012-04-25 |
Abbott Lab |
DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
|
CA2726087A1
(en)
|
2008-06-03 |
2009-12-10 |
Tariq Ghayur |
Dual variable domain immunoglobulins and uses thereof
|
US9109026B2
(en)
*
|
2008-06-03 |
2015-08-18 |
Abbvie, Inc. |
Dual variable domain immunoglobulins and uses thereof
|
EP2282770B1
(en)
*
|
2008-06-04 |
2018-03-07 |
MacroGenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
US8999702B2
(en)
*
|
2008-06-11 |
2015-04-07 |
Emd Millipore Corporation |
Stirred tank bioreactor
|
PL2307455T3
(pl)
|
2008-06-25 |
2017-09-29 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Optymalizacja rozpuszczalności cząsteczek immunowiążących
|
EP2310006A4
(en)
|
2008-07-03 |
2012-04-25 |
Mayo Foundation |
TREATMENT OF CANCER
|
KR101054362B1
(ko)
|
2008-07-03 |
2011-08-05 |
재단법인 목암생명공학연구소 |
재조합 단백질의 푸코스 함량을 감소시키는 방법
|
KR20110031369A
(ko)
*
|
2008-07-08 |
2011-03-25 |
아보트 러보러터리즈 |
프로스타글란딘 e2 이원 가변 도메인 면역글로불린 및 이의 용도
|
EP2982695B1
(en)
|
2008-07-09 |
2019-04-03 |
Biogen MA Inc. |
Compositions comprising antibodies to lingo or fragments thereof
|
KR101030978B1
(ko)
*
|
2008-07-10 |
2011-04-28 |
(주) 에이프로젠 |
동물세포용 재조합 발현벡터
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
TW201016233A
(en)
*
|
2008-07-15 |
2010-05-01 |
Genentech Inc |
Methods of treating autoimmune diseases using CD4 antibodies
|
KR20110033233A
(ko)
*
|
2008-07-21 |
2011-03-30 |
이뮤노메딕스, 인코오포레이티드 |
개선된 치료 특성을 갖는 항체의 구조 변이체
|
WO2010011281A2
(en)
*
|
2008-07-22 |
2010-01-28 |
The Research Foundation Of State University Of New York |
Methods and compositions for the diagnosis and treatment of cancer
|
LT2848625T
(lt)
|
2008-08-14 |
2019-10-10 |
Genentech, Inc. |
Priemaišų pašalinimo būdai, panaudojant reziduojančio baltymo pakeitimą jonų mainų membraninės chromatografijos pagalba
|
KR20110076918A
(ko)
|
2008-09-10 |
2011-07-06 |
제넨테크, 인크. |
단백질의 산화성 분해를 방지하기 위한 조성물 및 방법
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
AU2009309387A1
(en)
*
|
2008-10-28 |
2010-05-06 |
Avesthagen Limited |
An expression vector and processes thereof
|
CN102300879A
(zh)
*
|
2008-12-04 |
2011-12-28 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
GB2466025A
(en)
|
2008-12-08 |
2010-06-09 |
Univ Francois Rabelais De Tour |
C3/ITGAM polymorphisms and cancer prognosis
|
US8775090B2
(en)
|
2008-12-12 |
2014-07-08 |
Medimmune, Llc |
Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
|
ES2749232T3
(es)
|
2008-12-16 |
2020-03-19 |
Emd Millipore Corp |
Reactor de tanque agitado y procedimiento
|
WO2010074702A1
(en)
|
2008-12-16 |
2010-07-01 |
Millipore Corporation |
Purification of proteins
|
US8940276B2
(en)
|
2008-12-19 |
2015-01-27 |
Biogen Idec International Neuroscience Gmbh |
Human anti-alpha-synuclein antibodies
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
WO2010074724A1
(en)
|
2008-12-22 |
2010-07-01 |
Millennium Pharmaceuticals, Inc. |
Combination of aurora kinase inhibitors and anti-cd20 antibodies
|
US20120003235A1
(en)
|
2008-12-31 |
2012-01-05 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
US20110142836A1
(en)
*
|
2009-01-02 |
2011-06-16 |
Olav Mella |
B-cell depleting agents for the treatment of chronic fatigue syndrome
|
US20110275791A1
(en)
|
2009-01-06 |
2011-11-10 |
Ziad Mallat |
A B Cell Depleting Agent for the Treatment of Atherosclerosis
|
EP2400992B1
(en)
|
2009-02-27 |
2015-07-22 |
Genentech, Inc. |
Methods and compositions for protein labelling
|
CN105254758A
(zh)
|
2009-03-05 |
2016-01-20 |
Abbvie公司 |
Il-17结合蛋白
|
HUE029619T4
(en)
|
2009-03-10 |
2017-07-28 |
Biogen Ma Inc |
Anti-bcma antibodies
|
CN102369011A
(zh)
|
2009-03-12 |
2012-03-07 |
健泰科生物技术公司 |
用于治疗造血恶性肿瘤的磷酸肌醇3-激酶抑制剂化合物与化学治疗剂的组合
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
CA2756186A1
(en)
|
2009-03-24 |
2010-09-30 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against light and uses thereof
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
US8815242B2
(en)
*
|
2009-05-27 |
2014-08-26 |
Synageva Biopharma Corp. |
Avian derived antibodies
|
WO2010145846A1
(en)
|
2009-06-15 |
2010-12-23 |
Bayer Bioscience N.V. |
Nicotiana benthamiana plants deficient in xylosyltransferase activity
|
BRPI1015234A2
(pt)
|
2009-06-22 |
2018-02-20 |
Medimmune Llc |
regiões fc projetadas para conjugação sítio específica.
|
WO2011000543A1
(en)
*
|
2009-06-30 |
2011-01-06 |
Philochem Ag |
Murine antibody display library
|
UY32808A
(es)
*
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
RU2639288C2
(ru)
|
2009-08-11 |
2017-12-20 |
Дженентек, Инк. |
Получение белков в культуральных средах без глутамина
|
MA33470B1
(fr)
|
2009-08-14 |
2012-07-03 |
Hoffmann La Roche |
Polythérapie à base d'un anticorps afucosylé anti-cd20 et de fludarabine et/ou mitoxantrone
|
TWI409079B
(zh)
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
|
CN108409829A
(zh)
|
2009-09-01 |
2018-08-17 |
弗·哈夫曼-拉罗切有限公司 |
通过改进的a蛋白洗脱增强的蛋白质纯化
|
MX2012002651A
(es)
|
2009-09-01 |
2012-05-22 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
US8728730B2
(en)
*
|
2009-09-03 |
2014-05-20 |
Genentech, Inc. |
Methods for treating, diagnosing, and monitoring rheumatoid arthritis
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
SI2486141T1
(en)
|
2009-10-07 |
2018-06-29 |
Macrogenics, Inc. |
FC REGION-CONTAINING POLYPETHYDE, AFFECTING A BETTERED EFFECTORAL FUNCTION, BY CHANGES IN THE SCOPE OF FUKOZILATION AND METHODS FOR THEIR USE
|
PE20121531A1
(es)
|
2009-10-15 |
2012-12-22 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual
|
KR101536388B1
(ko)
*
|
2009-10-19 |
2015-07-22 |
에프. 호프만-라 로슈 아게 |
비-교차반응성 항-IgG 항체
|
EP2325185A1
(en)
|
2009-10-28 |
2011-05-25 |
GPC Biotech AG |
Plk inhibitor
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US20110189178A1
(en)
*
|
2010-02-04 |
2011-08-04 |
Xencor, Inc. |
Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
|
US20120309056A1
(en)
|
2010-02-04 |
2012-12-06 |
Leon Arnaud |
Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
TW201129383A
(en)
*
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
AR080154A1
(es)
|
2010-02-10 |
2012-03-14 |
Immunogen Inc |
Anticuerpos cd20 y su utilizacion
|
CA2791652C
(en)
|
2010-03-02 |
2018-06-12 |
Kyowa Hakko Kirin Co., Ltd. |
Modified antibody composition
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
SG183847A1
(en)
|
2010-03-04 |
2012-10-30 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
ES2722201T3
(es)
|
2010-03-22 |
2019-08-08 |
Hoffmann La Roche |
Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas
|
AU2011230590C1
(en)
|
2010-03-26 |
2016-09-15 |
Memorial Sloan-Kettering Cancer Center |
Antibodies to MUC16 and methods of use thereof
|
JP5767207B2
(ja)
|
2010-03-26 |
2015-08-19 |
協和発酵キリン株式会社 |
新規修飾部位導入抗体および抗体フラグメント
|
WO2011120134A1
(en)
|
2010-03-29 |
2011-10-06 |
Zymeworks, Inc. |
Antibodies with enhanced or suppressed effector function
|
EP2552967A4
(en)
|
2010-04-02 |
2014-10-08 |
Amunix Operating Inc |
BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
EP2563391B1
(en)
|
2010-04-27 |
2020-08-26 |
Roche Glycart AG |
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
|
WO2011139718A1
(en)
|
2010-05-03 |
2011-11-10 |
Genentech, Inc. |
Compositions and methods useful for reducing the viscosity of protein-containing formulations
|
EP2568976B1
(en)
|
2010-05-10 |
2015-09-30 |
Academia Sinica |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
TWI615405B
(zh)
|
2010-05-14 |
2018-02-21 |
艾伯維有限公司 |
Il-1結合蛋白
|
CN102892791B
(zh)
|
2010-05-17 |
2017-05-17 |
Emd密理博公司 |
用于纯化生物分子的刺激响应性聚合物
|
CA3209878A1
(en)
|
2010-05-25 |
2011-12-01 |
Genentech, Inc. |
Methods of purifying polypeptides
|
MX343604B
(es)
|
2010-05-28 |
2016-11-11 |
Genentech Inc |
Disminuir nivel de lactato e incrementar producción de polipéptidos por regulación a la baja de la expresión de lactato dehidrogenasa y piruvato dehidrogenasa quinasa.
|
ES2880802T3
(es)
|
2010-06-24 |
2021-11-25 |
Hoffmann La Roche |
Composiciones y procedimientos para estabilizar formulaciones que contienen proteínas
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
KR20140002601A
(ko)
|
2010-07-09 |
2014-01-08 |
바이오겐 이데크 헤모필리아 인코포레이티드 |
키메라 응고 인자
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
EP2598530A2
(en)
|
2010-07-29 |
2013-06-05 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
US20130130317A1
(en)
|
2010-08-02 |
2013-05-23 |
Kyowa Hakko Kirin Co., Ltd |
Method for producing substance
|
ES2667100T3
(es)
|
2010-08-02 |
2018-05-09 |
Macrogenics, Inc. |
Diacuerpos covalentes y sus usos
|
CN103298834A
(zh)
|
2010-08-03 |
2013-09-11 |
Abbvie公司 |
双重可变结构域免疫球蛋白及其用途
|
CA2806855A1
(en)
|
2010-08-03 |
2012-02-09 |
F. Hoffmann - La Roche Ag |
Chronic lymphocytic leukemia (cll) biomarkers
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EP2603525A1
(en)
|
2010-08-13 |
2013-06-19 |
F.Hoffmann-La Roche Ag |
Antibodies to il-1beta and il-18, for treatment of disease
|
AR082693A1
(es)
|
2010-08-17 |
2012-12-26 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
|
RU2603284C2
(ru)
*
|
2010-08-17 |
2016-11-27 |
Ф.Хоффманн-Ля Рош Аг |
АНТИТЕЛА ПРОТИВ IgG1 ЧЕЛОВЕКА
|
CA2809433A1
(en)
|
2010-08-26 |
2012-03-01 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
CA2821992A1
(en)
|
2010-10-01 |
2012-04-05 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
JP2014503178A
(ja)
|
2010-10-11 |
2014-02-13 |
バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー |
ヒト抗タウ抗体
|
MX2013005024A
(es)
|
2010-11-08 |
2013-11-21 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-il-6 receptor administrado subcutaneamente.
|
BR112013014949B1
(pt)
|
2010-12-15 |
2021-12-28 |
Inter-University Research Institute Corporation Research Organization Of Information And Systems |
Métodos para a produção de uma proteína de interesse e para a obtenção de uma suspensão de células cho capaz de sobreviver e proliferar em um meio sem soro que produz uma proteína de interesse
|
BR112013014522A2
(pt)
|
2010-12-16 |
2017-09-26 |
Roche Glycart Ag |
anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
|
EP3628689A1
(en)
|
2010-12-17 |
2020-04-01 |
Neurimmune Holding AG |
Human anti-sod1 antibodies
|
MX2013007332A
(es)
|
2010-12-21 |
2014-01-23 |
Abbvie Inc |
Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
|
EP3147355B1
(en)
|
2010-12-27 |
2020-07-22 |
Kyowa Kirin Co., Ltd. |
Method for preparing aqueous solution containing culture medium and chelating agent
|
WO2012095514A1
(en)
|
2011-01-14 |
2012-07-19 |
Vivalis |
Recombinant protein production system
|
WO2012106368A2
(en)
|
2011-01-31 |
2012-08-09 |
The Regents Of The University Of California |
Methods for inhibiting prostate cancer
|
MX353143B
(es)
|
2011-02-28 |
2017-12-20 |
Genentech Inc |
Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b.
|
TWI588156B
(zh)
|
2011-03-28 |
2017-06-21 |
賽諾菲公司 |
具有交叉結合區定向之雙重可變區類抗體結合蛋白
|
PT2691417T
(pt)
|
2011-03-29 |
2018-10-31 |
Roche Glycart Ag |
Variantes de fc de anticorpos
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
EP2506015A1
(en)
|
2011-04-01 |
2012-10-03 |
Universität Regensburg |
A prognostic and therapeutic signature for malignant melanoma
|
WO2012145183A2
(en)
|
2011-04-19 |
2012-10-26 |
Pfizer Inc. |
Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
|
HUE048876T2
(hu)
|
2011-05-09 |
2020-08-28 |
Mayo Found Medical Education & Res |
Rákos megbetegedések kezelése
|
US8679767B2
(en)
|
2011-05-12 |
2014-03-25 |
Genentech, Inc. |
Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
|
EP2710042A2
(en)
|
2011-05-16 |
2014-03-26 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
ES2732213T3
(es)
|
2011-05-21 |
2019-11-21 |
Macrogenics Inc |
Moléculas que se unen a CD3 capaces de unirse a CD3 humano y no humano
|
SG195073A1
(en)
|
2011-05-21 |
2013-12-30 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
RU2011122942A
(ru)
|
2011-06-08 |
2012-12-20 |
Общество С Ограниченной Ответственностью "Асинэкс Медхим" |
Новые ингибиторы киназ
|
PT2723379T
(pt)
|
2011-06-23 |
2018-11-14 |
Univ Of Zuerich |
Moléculas de ligação anti-alfa-sinucleína
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
CN103827143A
(zh)
|
2011-07-06 |
2014-05-28 |
莫弗系统股份公司 |
抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
|
JP6027104B2
(ja)
|
2011-07-08 |
2016-11-16 |
イー・エム・デイー・ミリポア・コーポレイシヨン |
使い捨てバイオテクノロジー方法のための改良されたデプスフィルター
|
WO2019071023A1
(en)
|
2017-10-04 |
2019-04-11 |
Yale University |
COMPOSITIONS AND METHODS FOR MAKING POLYPEPTIDES CONTAINING SELENOCYSTEINE
|
WO2013009868A1
(en)
|
2011-07-11 |
2013-01-17 |
Yale University |
Compositions and methods for making selenocysteine containing polypeptides
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
EP2550975A1
(en)
|
2011-07-29 |
2013-01-30 |
Sanofi |
Combination therapy for the treatment of CD19+ B-cell malignancies symptoms comprising an anti-CD19 maytansinoid immunoconjugate and rituximab
|
US9181532B2
(en)
|
2011-07-29 |
2015-11-10 |
Icon Genetics Gmbh |
Production of galactosylated N-glycans in plants
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2013049362A2
(en)
|
2011-09-27 |
2013-04-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
|
ES2911677T3
(es)
|
2011-10-03 |
2022-05-20 |
Modernatx Inc |
Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
|
JP6104252B2
(ja)
|
2011-10-04 |
2017-03-29 |
アイコン・ジェネティクス・ゲーエムベーハー |
フコシルトランスフェラーゼ活性が欠損したニコチアナ・ベンサミアナ植物
|
DK2766392T3
(da)
|
2011-10-10 |
2019-10-07 |
Xencor Inc |
Fremgangsmåde til oprensning af antistoffer
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
RU2014120981A
(ru)
|
2011-10-24 |
2015-12-10 |
Эббви Инк. |
Иммунные связывающие агенты против склеростина
|
EP2771694A4
(en)
|
2011-10-26 |
2015-08-05 |
Novartis Tiergesundheit Ag |
MONOCLONAL ANTIBODIES AND METHOD FOR THEIR USE
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
DE12858350T1
(de)
|
2011-12-16 |
2021-10-07 |
Modernatx, Inc. |
Modifizierte mrna zusammensetzungen
|
SG11201403437TA
(en)
|
2011-12-22 |
2014-07-30 |
Genentech Inc |
Ion exchange membrane chromatography
|
EP2797955A2
(en)
|
2011-12-30 |
2014-11-05 |
AbbVie Inc. |
Dual variable domain immunoglobulins against il-13 and/or il-17
|
WO2013116287A1
(en)
|
2012-01-31 |
2013-08-08 |
Genentech, Inc. |
Anti-ig-e m1' antibodies and methods using same
|
ES2652136T3
(es)
|
2012-02-16 |
2018-01-31 |
Atyr Pharma, Inc. |
Histidil-tRNA sintetasas para tratar enfermedades autoinmunitarias e inflamatorias
|
US20140080180A1
(en)
|
2012-03-27 |
2014-03-20 |
Genentech, Inc. |
Harvest operations for recombinant proteins
|
EP3501550A1
(en)
|
2012-04-02 |
2019-06-26 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins associated with human disease
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
AU2013262934B2
(en)
|
2012-05-14 |
2018-02-01 |
Biogen Ma Inc. |
LINGO-2 antagonists for treatment of conditions involving motor neurons
|
SI2859017T1
(sl)
|
2012-06-08 |
2019-05-31 |
Sutro Biopharma, Inc. |
Protitelesa, ki vsebujejo specifične nenaravne aminokislinske ostanke, postopki njihove priprave in postopki njihove uporabe
|
WO2013185114A2
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Chimeric clotting factors
|
TW201402608A
(zh)
|
2012-07-12 |
2014-01-16 |
Abbvie Inc |
Il-1結合蛋白質
|
ES2896493T3
(es)
|
2012-07-13 |
2022-02-24 |
Roche Glycart Ag |
Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
|
CA2880701A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
AU2013305827A1
(en)
|
2012-08-21 |
2015-03-05 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
ES2728864T3
(es)
|
2012-08-31 |
2019-10-29 |
Sutro Biopharma Inc |
Aminoácidos modificados que comprenden un grupo azido
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
WO2014052713A2
(en)
|
2012-09-27 |
2014-04-03 |
Massachusetts Institute Of Technology |
Her2-and vegf-a-binding proteins with enhanced stability
|
US10413606B2
(en)
|
2012-10-01 |
2019-09-17 |
Mayo Foundation For Medical Education And Research |
Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
|
KR20210063443A
(ko)
|
2012-10-09 |
2021-06-01 |
바이오젠 엠에이 인코포레이티드 |
탈수초성 질환의 치료를 위한 복합 요법 및 용도
|
ES2530968T3
(es)
|
2012-10-12 |
2015-03-09 |
Spirogen Sarl |
Pirrolobenzodiazepinas y conjugados de las mismas
|
CN104884472B
(zh)
|
2012-11-01 |
2021-10-15 |
艾伯维公司 |
抗-vegf/dll4双重可变结构域免疫球蛋白及其用途
|
SG11201503324WA
(en)
|
2012-11-01 |
2015-05-28 |
Abbvie Inc |
Stable dual variable domain immunoglobulin protein formulations
|
JP6437441B2
(ja)
|
2012-11-02 |
2018-12-12 |
ティージー セラピューティクス インコーポレイテッド |
抗cd20抗体およびpi3キナーゼ選択的阻害剤の組み合わせ
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
WO2014100095A1
(en)
|
2012-12-19 |
2014-06-26 |
Genentech, Inc. |
Methods and compositions for radiohalogen protein labeling
|
SG10201705104UA
(en)
|
2012-12-21 |
2017-07-28 |
Biogen Int Neuroscience Gmbh |
Human anti-tau antibodies
|
US9771413B2
(en)
|
2012-12-31 |
2017-09-26 |
Neurimmune Holding Ag |
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
RU2639505C2
(ru)
*
|
2013-01-24 |
2017-12-21 |
ЭбТЛАС КО., Лтд. |
Библиотека fv на основе комбинаций белков и способ ее получения
|
CN105209068A
(zh)
|
2013-02-07 |
2015-12-30 |
免疫医疗公司 |
用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox)
|
DK3889173T3
(da)
|
2013-02-15 |
2023-10-09 |
Bioverativ Therapeutics Inc |
Optimeret faktor viii-gen
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
CN105209077B
(zh)
|
2013-03-13 |
2019-06-11 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓以及其结合物
|
CA2906057A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Antibody formulations
|
CN111925437A
(zh)
|
2013-03-14 |
2020-11-13 |
宏观基因有限公司 |
与表达激活受体的免疫效应细胞具有免疫反应性的双特异性分子
|
WO2014144280A2
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Inc. |
DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
|
MX368665B
(es)
|
2013-03-15 |
2019-10-10 |
Abbvie Biotherapeutics Inc |
Variantes de fc.
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
UY35463A
(es)
|
2013-03-15 |
2014-10-31 |
Biogen Idec Inc |
Formulaciones de polipéptido fc-factor ix.
|
WO2014169078A2
(en)
|
2013-04-09 |
2014-10-16 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
HUE058364T2
(hu)
|
2013-04-19 |
2022-07-28 |
Cytune Pharma |
Citokinbõl származó kezelés redukált vaszkuláris permeabilitási szindrómával
|
EP2805730A1
(en)
|
2013-05-21 |
2014-11-26 |
Bergen Teknologioverforing AS |
Nitric oxide donor for the treatment of chronic fatigue syndrome
|
AU2014273817B2
(en)
|
2013-05-31 |
2019-03-14 |
Zymeworks Bc Inc. |
Heteromultimers with reduced or silenced effector function
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
ES2865473T3
(es)
|
2013-07-10 |
2021-10-15 |
Sutro Biopharma Inc |
Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
US11384149B2
(en)
|
2013-08-09 |
2022-07-12 |
Macrogenics, Inc. |
Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
|
EP2840091A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
|
EP2839842A1
(en)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
US9782476B2
(en)
|
2013-09-06 |
2017-10-10 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
CA2923859C
(en)
|
2013-09-11 |
2021-11-23 |
Arsia Therapeutics, Inc. |
Liquid protein formulations containing viscosity-lowering agents
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
EP3055298B1
(en)
|
2013-10-11 |
2020-04-29 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
CN105813637A
(zh)
|
2013-11-01 |
2016-07-27 |
卑尔根技术转移公司 |
用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂
|
CN106414494B
(zh)
|
2013-11-12 |
2020-09-18 |
Ogd2药物 |
具有促凋亡活性的人IgG1衍生的抗体
|
BR112016013741A2
(pt)
|
2013-12-17 |
2017-10-03 |
Genentech Inc |
Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015109180A2
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
EP3110445A4
(en)
|
2014-02-25 |
2017-09-27 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
EP2915569A1
(en)
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
TWI687428B
(zh)
|
2014-03-27 |
2020-03-11 |
中央研究院 |
反應性標記化合物及其用途
|
EA201691925A1
(ru)
|
2014-03-28 |
2017-06-30 |
Ксенкор, Инк. |
Биспецифические антитела, которые связываются с cd38 и cd3
|
WO2015164758A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Florida Research Foundation, Inc. |
Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
JP7062361B2
(ja)
|
2014-05-27 |
2022-05-06 |
アカデミア シニカ |
抗her2糖操作抗体群およびその使用
|
CN106573971A
(zh)
|
2014-05-27 |
2017-04-19 |
中央研究院 |
抗cd20醣抗体及其用途
|
JP7093612B2
(ja)
|
2014-05-27 |
2022-06-30 |
アカデミア シニカ |
Bacteroides由来のフコシダーゼおよびそれを使用する方法
|
JP7063538B2
(ja)
|
2014-05-28 |
2022-05-09 |
アカデミア シニカ |
抗TNFα糖操作抗体群およびその使用
|
JP6695286B2
(ja)
|
2014-06-13 |
2020-05-20 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
リンパ腫の処置
|
EA201692502A1
(ru)
|
2014-06-16 |
2017-09-29 |
Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч |
Лечение миелом
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
PL3166401T3
(pl)
|
2014-07-09 |
2021-01-25 |
F. Hoffmann-La Roche Ag |
Dostosowanie pH w celu poprawy wyników regeneracji banków komórek po rozmrożeniu
|
AU2015315294B2
(en)
|
2014-09-08 |
2020-09-17 |
Academia Sinica |
Human iNKT cell activation using glycolipids
|
WO2016037947A1
(en)
|
2014-09-10 |
2016-03-17 |
F. Hoffmann-La Roche Ag |
Galactoengineered immunoglobulin 1 antibodies
|
CN106687141A
(zh)
|
2014-09-10 |
2017-05-17 |
麦迪穆有限责任公司 |
吡咯并苯并二氮杂卓及其缀合物
|
WO2016044334A1
(en)
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Antibody formulations
|
CA3069221C
(en)
|
2014-09-23 |
2023-04-04 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
MX2017004076A
(es)
|
2014-09-29 |
2017-07-04 |
Univ Duke |
Moleculas biespecificas que comprenden un brazo orientado a la envoltura vih-1.
|
NZ729808A
(en)
|
2014-09-30 |
2022-02-25 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (dprs) antibody
|
SG10201902915VA
(en)
|
2014-10-01 |
2019-04-29 |
Eagle Biologics Inc |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
US9446148B2
(en)
|
2014-10-06 |
2016-09-20 |
Mayo Foundation For Medical Education And Research |
Carrier-antibody compositions and methods of making and using the same
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
ES2809455T3
(es)
|
2014-11-17 |
2021-03-04 |
Regeneron Pharma |
Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
|
PE20171103A1
(es)
|
2014-11-26 |
2017-08-07 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y cd38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
BR112017011092A2
(pt)
|
2014-11-26 |
2017-12-26 |
Xencor Inc |
anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
JP2018504400A
(ja)
|
2015-01-08 |
2018-02-15 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
Lingo‐1拮抗薬及び脱髄障害の治療のための使用
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
TWI736523B
(zh)
|
2015-01-24 |
2021-08-21 |
中央研究院 |
新穎聚醣結合物及其使用方法
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
RU2758113C2
(ru)
|
2015-03-17 |
2021-10-26 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Антитела к muc16 и их применение
|
US10722523B2
(en)
|
2015-03-17 |
2020-07-28 |
The Regents Of The University Of California |
Chemoimmunotherapy for epithelial cancer
|
WO2016183104A1
(en)
|
2015-05-11 |
2016-11-17 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
MX2017015493A
(es)
|
2015-05-30 |
2018-02-09 |
Molecular Templates Inc |
Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden.
|
MX2017015618A
(es)
|
2015-06-03 |
2018-08-15 |
Boston Biomedical Inc |
Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer.
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
IL302486A
(en)
|
2015-06-24 |
2023-06-01 |
Hoffmann La Roche |
Antibodies against the transnephrine receptor with adapted affinity
|
EP3108897A1
(en)
|
2015-06-24 |
2016-12-28 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
|
US20170029520A1
(en)
|
2015-06-29 |
2017-02-02 |
Genentech, Inc. |
Compositions and methods for use in organ transplantation
|
AU2016301303B2
(en)
|
2015-08-03 |
2021-10-07 |
Bioverativ Therapeutics Inc. |
Factor IX fusion proteins and methods of making and using same
|
EP3334747B1
(en)
|
2015-08-13 |
2023-09-27 |
Amgen Inc. |
Charged depth filtration of antigen-binding proteins
|
TW201707725A
(zh)
|
2015-08-18 |
2017-03-01 |
美國馬友醫藥教育研究基金會 |
載體-抗體組合物及其製造及使用方法
|
EP4129327A1
(en)
|
2015-08-28 |
2023-02-08 |
Amunix Pharmaceuticals, Inc. |
Chimeric polypeptide assembly and methods of making and using the same
|
CN108367004B
(zh)
|
2015-09-21 |
2022-09-13 |
阿帕特夫研究和发展有限公司 |
Cd3结合多肽
|
MX2018003822A
(es)
|
2015-10-02 |
2018-06-22 |
Hoffmann La Roche |
Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
TW201713360A
(en)
|
2015-10-06 |
2017-04-16 |
Mayo Foundation |
Methods of treating cancer using compositions of antibodies and carrier proteins
|
US11472876B2
(en)
|
2015-11-02 |
2022-10-18 |
Bioatla, Inc. |
Conditionally active polypeptides
|
US10227410B2
(en)
|
2015-12-07 |
2019-03-12 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
AU2016380988B2
(en)
|
2015-12-30 |
2022-07-21 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
WO2017120501A1
(en)
|
2016-01-07 |
2017-07-13 |
Mayo Foundation For Medical Education And Research |
Methods of treating cancer with interferon
|
PT3411478T
(pt)
|
2016-02-01 |
2022-09-13 |
Bioverativ Therapeutics Inc |
Genes do fator viii otimizados
|
US11351254B2
(en)
|
2016-02-12 |
2022-06-07 |
Mayo Foundation For Medical Education And Research |
Hematologic cancer treatments
|
JP2019517991A
(ja)
|
2016-03-01 |
2019-06-27 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
低減したadcpを有するオビヌツズマブ及びリツキシマブ変異体
|
EP3423593A1
(en)
|
2016-03-02 |
2019-01-09 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and kits for predicting the risk of relapse in patients suffering from idiopathic nephrotic syndrome
|
JP2019515876A
(ja)
|
2016-03-08 |
2019-06-13 |
アカデミア シニカAcademia Sinica |
N−グリカンおよびそのアレイのモジュール合成のための方法
|
TN2018000301A1
(en)
|
2016-03-14 |
2020-01-16 |
Univ Oslo |
Engineered immunoglobulins with altered fcrn binding
|
US10870701B2
(en)
|
2016-03-15 |
2020-12-22 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
CA3018340A1
(en)
|
2016-03-21 |
2017-09-28 |
Mayo Foundation For Medical Education And Research |
Methods for improving the therapeutic index for a chemotherapeutic drug
|
AU2017238119A1
(en)
|
2016-03-21 |
2018-10-11 |
Mayo Foundation For Medical Education And Research |
Methods for reducing toxicity of a chemotherapeutic drug
|
JP2019510517A
(ja)
|
2016-03-29 |
2019-04-18 |
ジェルター, インコーポレイテッド |
細胞質内体積に対するペリプラズム体積の比率が0.5:1および10:1の間にあるグラム陰性細菌におけるタンパク質の発現
|
US10618969B2
(en)
|
2016-04-06 |
2020-04-14 |
Mayo Foundation For Medical Education And Research |
Carrier-binding agent compositions and methods of making and using the same
|
EP3442574A4
(en)
|
2016-04-15 |
2019-12-11 |
MacroGenics, Inc. |
NOVEL B7-H3 BINDING MOLECULES, THEIR ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE
|
EP3445378A1
(en)
|
2016-04-22 |
2019-02-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and vaccine compositions for the treatment of b-cell malignancies
|
CA3024123A1
(en)
|
2016-05-27 |
2017-11-30 |
Tg Therapeutics, Inc. |
Combination of anti-cd20 antibody, p13 kinase-delta selective inhibitor, and btk inhibitor to treat b-cell proliferative disorders
|
MX2018015592A
(es)
|
2016-06-14 |
2019-04-24 |
Xencor Inc |
Anticuerpos inhibidores de puntos de control biespecificos.
|
WO2017218698A1
(en)
|
2016-06-15 |
2017-12-21 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
JP7021127B2
(ja)
|
2016-06-28 |
2022-02-16 |
ゼンコア インコーポレイテッド |
ソマトスタチン受容体2に結合するヘテロ二量体抗体
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
MA45668A
(fr)
|
2016-07-13 |
2019-05-22 |
Biogen Ma Inc |
Schémas posologiques d'antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
|
GB201613167D0
(en)
|
2016-07-29 |
2016-09-14 |
Univ Southampton |
Cancer and b-cell related disease therapy
|
US10538592B2
(en)
|
2016-08-22 |
2020-01-21 |
Cho Pharma, Inc. |
Antibodies, binding fragments, and methods of use
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
CN107384932B
(zh)
|
2016-08-31 |
2020-10-20 |
北京天广实生物技术股份有限公司 |
抗人cd20人源化单克隆抗体mil62、其制备方法及用途
|
CA3035378A1
(en)
|
2016-09-01 |
2018-03-08 |
Mayo Foundation For Medical Education And Research |
Carrier-pd-l1 binding agent compositions for treating cancers
|
CN109843336A
(zh)
|
2016-09-01 |
2019-06-04 |
梅约医学教育与研究基金会 |
用于靶向t细胞癌症的方法和组合物
|
EP3510048A1
(en)
|
2016-09-06 |
2019-07-17 |
Mayo Foundation for Medical Education and Research |
Methods of treating pd-l1 expressing cancer
|
WO2018048958A1
(en)
|
2016-09-06 |
2018-03-15 |
Mayo Foundation For Medical Education And Research |
Paclitaxel-albumin-binding agent compositions and methods for using and making the same
|
US11590098B2
(en)
|
2016-09-06 |
2023-02-28 |
Mayo Foundation For Medical Education And Research |
Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
|
KR20190068521A
(ko)
|
2016-09-09 |
2019-06-18 |
티지 쎄라퓨틱스, 인코포레이티드 |
혈액암을 치료하기 위한 항-cd20 항체, pi3 키나아제-델타 억제제, 및 항-pd-1 또는 항-pd-l1 항체의 조합
|
CN108421048B
(zh)
*
|
2016-09-28 |
2021-04-20 |
首都医科大学附属北京世纪坛医院 |
纳米活性碳靶向药物递送系统、制备方法及其用途
|
JP2019534882A
(ja)
|
2016-10-11 |
2019-12-05 |
メドイミューン・リミテッドMedImmune Limited |
免疫介在性療法薬を有する抗体−薬物コンジュゲート
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
WO2018102427A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
WO2018100096A1
(en)
|
2016-12-01 |
2018-06-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Use of anti-uchl1 igg plasma concentration for diagnosing idiopathic steroid sensitive nephrotic syndrome
|
EP3548066A1
(en)
|
2016-12-02 |
2019-10-09 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
BR112019011198A2
(pt)
|
2016-12-02 |
2019-12-17 |
Bioverativ Therapeutics Inc |
métodos de indução de tolerância imune a fatores de coagulação
|
TW201831521A
(zh)
|
2017-01-31 |
2018-09-01 |
美商生物化學醫療公司 |
因子ix融合蛋白以及其製備方法及使用方法
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
EP3606964A4
(en)
|
2017-04-03 |
2020-12-09 |
Immunomedics, Inc. |
SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
|
EP3624846A1
(en)
|
2017-05-16 |
2020-03-25 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
JP2020520923A
(ja)
|
2017-05-17 |
2020-07-16 |
ボストン バイオメディカル, インコーポレイテッド |
がんを処置するための方法
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
WO2019011918A1
(en)
|
2017-07-10 |
2019-01-17 |
International - Drug - Development - Biotech |
TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
|
JP2020528061A
(ja)
|
2017-07-26 |
2020-09-17 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
|
US10759865B2
(en)
|
2017-08-22 |
2020-09-01 |
Eyal Levit |
Treatment of diabetes mellitus
|
US11180541B2
(en)
|
2017-09-28 |
2021-11-23 |
Geltor, Inc. |
Recombinant collagen and elastin molecules and uses thereof
|
WO2019077123A1
(en)
|
2017-10-20 |
2019-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND KITS FOR IDENTIFYING WHETHER A SUBJECT IS REACHED OR RISK OF BEING WITH AUTOIMMUNE MYOPATHY
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
JP2021506291A
(ja)
|
2017-12-19 |
2021-02-22 |
ゼンコア インコーポレイテッド |
改変されたil−2 fc融合タンパク質
|
EP3765489A1
(en)
|
2018-03-13 |
2021-01-20 |
F. Hoffmann-La Roche AG |
Therapeutic combination of 4-1 bb agonists with anti-cd20 antibodies
|
TW202003551A
(zh)
|
2018-03-28 |
2020-01-16 |
美商必治妥美雅史谷比公司 |
介白素-2/介白素-2受體阿法融合蛋白及其使用方法
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
CA3097741A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
EP3796942A1
(en)
|
2018-05-23 |
2021-03-31 |
ADC Therapeutics SA |
Molecular adjuvant
|
BR112020025623A2
(pt)
|
2018-07-03 |
2021-03-23 |
Bristol-Myers Squibb Company |
métodos de produção de proteínas recombinantes
|
US20210186880A1
(en)
|
2018-08-03 |
2021-06-24 |
Brown University |
Oral formulations with increased uptake
|
CN109273050B
(zh)
*
|
2018-08-03 |
2021-07-13 |
五邑大学 |
一种用于解析复杂多聚体蛋白受体的脉冲电子顺磁共振数据的系统及方法与应用
|
KR20210054528A
(ko)
|
2018-08-31 |
2021-05-13 |
리제너론 파아마슈티컬스, 인크. |
Cd3/c20 이중특이적 항체에 대한 사이토카인 방출 증후군을 경감시키는 투약 전략
|
WO2020061048A1
(en)
|
2018-09-17 |
2020-03-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses
|
EP3861016A2
(en)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Il-12 heterodimeric fc-fusion proteins
|
KR20210074341A
(ko)
|
2018-10-10 |
2021-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
고밀도 생물 반응기 배양에서 막 기체 전달을 위한 방법
|
GB201816553D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
GB201816554D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
US20210340277A1
(en)
|
2018-10-11 |
2021-11-04 |
The Scripps Research Institute |
Antibody compounds with reactive arginine and related antibody drug conjugates
|
KR102262012B1
(ko)
|
2018-10-15 |
2021-06-09 |
연세대학교 산학협력단 |
생산성이 향상된 항체 및 이의 제조방법
|
RU2724469C2
(ru)
|
2018-10-31 |
2020-06-23 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с cd20
|
WO2020091041A1
(ja)
|
2018-11-02 |
2020-05-07 |
協和キリン株式会社 |
液体培地の調製方法
|
AU2019385497A1
(en)
|
2018-11-20 |
2021-06-17 |
Cornell University |
Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
|
BR112021010908A2
(pt)
|
2018-12-06 |
2021-08-31 |
Genentech, Inc. |
Método para tratamento de linfoma difuso de grandes células b, kit e imunoconjugado
|
WO2020115262A1
(en)
|
2018-12-07 |
2020-06-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
|
WO2020160323A2
(en)
|
2019-01-31 |
2020-08-06 |
Elektrofi, Inc. |
Particle formation and morphology
|
SG11202108560RA
(en)
|
2019-02-13 |
2021-09-29 |
Brigham & Womens Hospital Inc |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
BR112021016348A2
(pt)
|
2019-02-18 |
2021-11-23 |
Atb Therapeutics |
Método de produção de uma proteína de fusão ligante-toxina em uma célula de planta ou em uma planta inteira
|
CN113710706A
(zh)
|
2019-02-27 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
|
CN114173875A
(zh)
|
2019-03-01 |
2022-03-11 |
Xencor股份有限公司 |
结合enpp3和cd3的异二聚抗体
|
JP2022521840A
(ja)
|
2019-04-01 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
タンパク質含有製剤を安定化するための組成物および方法
|
WO2020210440A1
(en)
|
2019-04-12 |
2020-10-15 |
Geltor, Inc. |
Recombinant elastin and production thereof
|
BR112021022815A2
(pt)
|
2019-05-14 |
2021-12-28 |
Genentech Inc |
Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina
|
EP3980423A1
(en)
|
2019-06-10 |
2022-04-13 |
Sutro Biopharma, Inc. |
5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
|
WO2020257235A1
(en)
|
2019-06-17 |
2020-12-24 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
KR20220039777A
(ko)
|
2019-08-01 |
2022-03-29 |
브리스톨-마이어스 스큅 컴퍼니 |
유가식 세포 배양에서 단백질 생산성을 개선시키는 방법
|
EP4021457A1
(en)
|
2019-08-30 |
2022-07-06 |
Vestlandets Innovasjonsselskap AS |
Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
|
TW202118512A
(zh)
|
2019-09-12 |
2021-05-16 |
美商建南德克公司 |
治療狼瘡性腎炎之組成物及方法
|
AU2020344675A1
(en)
|
2019-09-13 |
2022-03-31 |
Elektrofi, Inc. |
Compositions and methods for the delivery of therapeutic biologics for treatment of disease
|
CA3153880A1
(en)
|
2019-10-18 |
2020-06-09 |
Juana Elva HERNANDEZ MONTALVO |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
WO2021100034A1
(en)
|
2019-11-19 |
2021-05-27 |
Protalix Ltd. |
Removal of constructs from transformed cells
|
US20230090868A1
(en)
|
2020-01-31 |
2023-03-23 |
Seagen Inc. |
Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
|
WO2021168271A1
(en)
|
2020-02-19 |
2021-08-26 |
Elektrofi, Inc. |
Droplet formation and particle morphology
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
CN115484934A
(zh)
|
2020-04-17 |
2022-12-16 |
伊勒卓菲公司 |
通过连续液滴形成和脱水形成颗粒的方法
|
EP4139359A1
(en)
|
2020-04-24 |
2023-03-01 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
MX2022012973A
(es)
|
2020-04-26 |
2022-11-09 |
Biocytogen Pharmaceuticals Beijing Co Ltd |
Inmunoglobulinas modificadas.
|
JP2023523372A
(ja)
|
2020-05-03 |
2023-06-02 |
シャンハイ ミラコーケン インコーポレイティド |
抗体-薬物コンジュゲート及びその調製物
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
GB202007842D0
(en)
|
2020-05-26 |
2020-07-08 |
Quell Therapeutics Ltd |
Polypeptide useful in adoptive cell therapy
|
EP4189121A1
(en)
|
2020-08-03 |
2023-06-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
GB202012331D0
(en)
|
2020-08-07 |
2020-09-23 |
Petmedix Ltd |
Therapeutic antibodies
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
CN112062855A
(zh)
|
2020-08-26 |
2020-12-11 |
康诺亚生物医药科技(成都)有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
WO2022043415A1
(en)
|
2020-08-27 |
2022-03-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for detecting the presence of pemphigus-specific autoantibodies in a sample
|
GB202013477D0
(en)
|
2020-08-27 |
2020-10-14 |
Quell Therapeutics Ltd |
Nucleic acid constructs for expressing polypeptides in cells
|
US20230312757A1
(en)
|
2020-09-10 |
2023-10-05 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
|
KR20230066583A
(ko)
|
2020-09-10 |
2023-05-16 |
젠맵 에이/에스 |
미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
|
AU2021339954A1
(en)
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibody against CD3 and CD20 in combination therapy for treating follicular lymphoma
|
US20230357440A1
(en)
|
2020-09-10 |
2023-11-09 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
WO2022053657A1
(en)
|
2020-09-10 |
2022-03-17 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
US20230357815A1
(en)
|
2020-09-22 |
2023-11-09 |
Bristol-Myers Squibb Company |
Methods for increasing productivity of therapeutic proteins
|
KR20230113283A
(ko)
|
2020-10-05 |
2023-07-28 |
프로탈릭스 리미티드 |
다이서-유사 넉아웃 식물 세포
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
WO2022103983A2
(en)
|
2020-11-11 |
2022-05-19 |
Sutro Biopharma, Inc. |
Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
|
US20220143026A1
(en)
|
2020-11-12 |
2022-05-12 |
Tg Therapeutics, Inc. |
Triple combination to treat b-cell malignancies
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
BR112023018621A2
(pt)
|
2021-03-15 |
2023-10-24 |
Hoffmann La Roche |
Métodos para tratar nefrite lúpica, esgotar células b periféricas, kits para tratar nefrite lúpica e anticorpos anti-cd20 tipo ii
|
US20240165153A1
(en)
|
2021-03-24 |
2024-05-23 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof
|
WO2022224980A1
(ja)
|
2021-04-20 |
2022-10-27 |
日本メジフィジックス株式会社 |
抗cd20抗体の放射性複合体、及び、放射性医薬
|
EP4334354A1
(en)
|
2021-05-06 |
2024-03-13 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against alk and methods of use thereof
|
IL308351A
(en)
|
2021-05-12 |
2024-01-01 |
Genentech Inc |
Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
|
WO2022253756A1
(en)
|
2021-06-01 |
2022-12-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of b cell depleting agents for the treatment of rheumatic heart disease
|
AU2022291369A1
(en)
|
2021-06-08 |
2023-12-07 |
Xyphos Biosciences Inc. |
Antibody-nkg2d ligand domain fusion protein
|
KR20240018435A
(ko)
|
2021-06-08 |
2024-02-13 |
사이포스 바이오사이언시스 인코포레이티드 |
항체-nkg2d 리간드 도메인 융합 단백질
|
WO2022263864A1
(en)
|
2021-06-17 |
2022-12-22 |
Petmedix Ltd |
Anti canine cd20 antibodies
|
CA3220318A1
(en)
|
2021-06-17 |
2022-12-22 |
Glaxosmithkline Intellectual Property Limited |
Anti-baff antibodies for use in a method of treatment of long covid and/or post-acute sequelae sars-cov-2 infection (pasc)
|
WO2023010060A2
(en)
|
2021-07-27 |
2023-02-02 |
Novab, Inc. |
Engineered vlrb antibodies with immune effector functions
|
WO2023015234A1
(en)
|
2021-08-05 |
2023-02-09 |
Bristol-Myers Squibb Company |
Cell culture methods for producing therapeutic proteins
|
AU2022321899A1
(en)
|
2021-08-06 |
2024-02-08 |
Petmedix Ltd |
Antibody fc variants
|
TW202337499A
(zh)
|
2021-08-07 |
2023-10-01 |
美商建南德克公司 |
使用抗cd79b免疫結合物治療瀰漫性大b細胞淋巴瘤之方法
|
AU2022332276A1
(en)
|
2021-08-23 |
2024-04-04 |
Bioverativ Therapeutics Inc. |
Optimized factor viii genes
|
IL310963A
(en)
|
2021-08-23 |
2024-04-01 |
Bioverativ Therapeutics Inc |
Production of closed DNA with inverted repeat sequences
|
WO2023049687A1
(en)
|
2021-09-21 |
2023-03-30 |
Bristol-Myers Squibb Company |
Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
|
WO2023056331A1
(en)
|
2021-09-30 |
2023-04-06 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
AU2022396272A1
(en)
|
2021-11-24 |
2024-06-06 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
CA3241407A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
US20230303693A1
(en)
|
2022-01-28 |
2023-09-28 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
WO2023150552A1
(en)
|
2022-02-04 |
2023-08-10 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treatment of neurological disorders
|
WO2023152486A1
(en)
|
2022-02-09 |
2023-08-17 |
Petmedix Ltd |
Therapeutic antibodies
|
WO2023164487A1
(en)
|
2022-02-22 |
2023-08-31 |
Brown University |
Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
|
WO2023198635A1
(en)
|
2022-04-11 |
2023-10-19 |
Astrazeneca Ab |
T cell binding proteins
|
WO2023212721A1
(en)
|
2022-04-29 |
2023-11-02 |
Elektrofi, Inc. |
Injectable suspensions
|
US11884740B1
(en)
|
2022-06-01 |
2024-01-30 |
Tg Therapeutics, Inc. |
Anti-CD20 antibody compositions
|
US11807689B1
(en)
|
2022-06-01 |
2023-11-07 |
Tg Therapeutics, Inc. |
Anti-CD20 antibody compositions
|
US11965032B1
(en)
|
2022-06-01 |
2024-04-23 |
Tg Therapeutics, Inc. |
Anti-CD20 antibody compositions
|
US11814439B1
(en)
|
2022-06-01 |
2023-11-14 |
Tg Therapeutics, Inc. |
Anti-CD20 antibody compositions
|
US20240091365A1
(en)
|
2022-06-27 |
2024-03-21 |
Sutro Biopharma, Inc. |
Beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
|
WO2024015229A1
(en)
|
2022-07-15 |
2024-01-18 |
Sutro Biopharma, Inc. |
Protease/enzyme cleavable linker-payloads and protein conjugates
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|